verywellhealth18h
Zunveyl: An Improved Alzheimer's Drug With Fewer Side Effects Will Be Available Soon
Zunveyl, an oral medication, is a better-tolerated version of galantamine for managing mild to moderate Alzheimer's symptoms.
Alpha Cognition makes strategic personnel appointments to support ZUNVEYL launch
Alpha Cognition (ACOG) announced the strategic appointments of Jen Pesa, Vice President of Commercial; Jack Kelly, Head of Market Access; ...
Alpha Cognition Expands Commercial and Medical Teams with Key Leadership Hires to Support the Launch of ZUNVEYL
With these key hires, Alpha Cognition is poised to advance its mission of improving the lives of patients and families ...
Dallas Innovates5d
Muscling Up Dogs: Westlake-Based Virbac NA Launches Soft Chews That Improve Canine Mobility
Virbac said that URSOLYX Soft Chews targets mRNA expression in skeletal muscle, harnessing the proven benefits of ursolic ...
Dallas Innovates5d
Alpha Cognition Inks $44M Licensing Agreement With China’s CMS for Alpha’s ZUNVEYL Alzheimer’s Drug
The agreement with China Medical System Holdings Limited is for the development, manufacturing, and commercialization of ...
Alpha Cognition Inks $44 Million Licensing Pact For Its Alzheimer's Drug In China
Alpha Cognition Inc. (NASDAQ:ACOG) and China Medical System Holdings Limited announced an exclusive licensing agreement for ...
ENDPOINTS NEWS6d
Sana’s stock soars on new cell ther­a­py da­ta; UniQure’s $75M of­fer­ing
Sana stock soars on diabetes therapy data, UniQure's offering, BioInvent's lymphoma success, Alpha's Zunveyl deal, Neumirna funding, and Cassava's layoffs.
China Medical System （00867）Obtained New Drug ZUNVEYL for the Treatment of Mild-to-Moderate Dementia of the Alzheimer’s Type
As the second oral therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of Alzheimer’s disease during the past decade, ZUNVEYL demonstrates a potentially better safety ...